Yahoo Web Search

Search results

1. • • Sab Biotherapeutics (NASDAQ: SABS) is owned by 33.88% institutional shareholders, 566.36% Sab Biotherapeutics insiders, and 0.00% retail investors. Christine E. Hamilton is the largest individual Sab Biotherapeutics shareholder, owning 11.24M shares representing 121.76% of the company.
     Reference:

     Sab Biotherapeutics Inc Stock Ownership - Who owns Sab ...

2. www.wallstreetzen.com › stocks › usSab Biotherapeutics Inc Stock Ownership - Who owns Sab ...

   www.wallstreetzen.com › stocks › us

   • Cached

   Sab Biotherapeutics (NASDAQ: SABS) is owned by 33.88% institutional shareholders, 566.36% Sab Biotherapeutics insiders, and 0.00% retail investors. Christine E. Hamilton is the largest individual Sab Biotherapeutics shareholder, owning 11.24M shares representing 121.76% of the company.

3. SAB Biotherapeutics, Inc.

   NasdaqCM: SABS

   2.8400

   Add to watchlist

   Sign in to add to watchlist

   Sign In

   +0.0500 (+1.79%)

   At close: Fri. Sep 6, 2024 4:00 PM EDT · Delayed Quote (USD) · Market closed

   Full chart

   • 1D
   • 5D
   • 1M
   • 6M
   • YTD
   • 1Y
   • MAX

   • Open	2.9250
     High	2.9500
     Low	2.7001

   • Mkt Cap	26.21M
     P/E (TTM)	N/A
     Div & Yield	N/A & N/A

   • Prev. Close	2.7900
     52 Wk. Low	2.1600
     52 Wk. High	10.5000

   More about SABS

   Related stocks

   • BTTX
     Better Therapeutics, Inc.
     BTTX
     0.0001
     0.00%
   • BBLG
     Bone Biologics Corporation
     BBLG
     1.1900
     -4.03%
   • INAB
     IN8bio, Inc.
     INAB
     0.3040
     -10.03%
   • RNXT
     RenovoRx, Inc.
     RNXT
     1.0200
     +2.00%
   • SRZN
     Surrozen, Inc.
     SRZN
     9.23
     -5.11%

   More on Yahoo Finance

4. People also ask

   Where can I find information about SAB Biotherapeutics?

   • The Investor Relations website contains information about SAB Biotherapeutics's business for stockholders, potential investors, and financial analysts.

   Investor Relations | SAB Biotherapeutics

   ir.sab.bio/

   See all results for this question

   What is SAB bio?

   • SAB BIO is a clinical-stage biopharmaceutical company working to treat and prevent immune and autoimmune disorders. Founded in 2014 and traded on NASDAQ (SABS) since 2021, SAB BIO’s innovative genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma.

   Investor Relations | SAB Biotherapeutics

   ir.sab.bio/

   See all results for this question

   Should I buy SAB Biotherapeutics (SABS) stock?

   • Based on the current 2 buy ratings for SAB Biotherapeutics (SABS) in the last year, the consensus rating is Buy. The average twelve-month price prediction is $3.67, with a high price target of $4.00 and a low price target of $3.00.

   SAB Biotherapeutics Price Target & Analyst Ratings (NASDAQ

   www.marketbeat.com/stocks/nasdaq/sabs/price-target/

   See all results for this question

   What is the cost of SAB Biotherapeutics (SAB)?

   • The average twelve-month price prediction for SAB Biotherapeutics (SAB) is $3.67, with a high price target of $4.00 and a low price target of $3.00.

   SAB Biotherapeutics Price Target & Analyst Ratings (NASDAQ

   www.marketbeat.com/stocks/nasdaq/sabs/price-target/

   See all results for this question

5. www.sab.bio › home › about-usCompany Profile - SAB BIO

   www.sab.bio › home › about-us

   • Cached

   Founded in 2014 and traded on NASDAQ (SABS) since 2021, SAB BIO’s innovative genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma.

6. ir.sab.bioInvestor Relations | SAB Biotherapeutics

   ir.sab.bio

   • Cached

   Jun 14, 2023 · Founded in 2014 and traded on NASDAQ (SABS) since 2021, SAB BIO’s innovative genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma.

7. www.tipranks.com › stocks › sabsWho owns SAB Biotherapeutics? SABS Stock Ownership - TipRanks

   www.tipranks.com › stocks › sabs

   • Cached

   Peter Kolchinsky owns the most shares of SAB Biotherapeutics (SABS). What is the significance of the ownership structure for a publicly traded company? The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price ...

8. stockanalysis.com › stocks › sabsSAB Biotherapeutics, Inc. (SABS) Company Profile & Overview ...

   stockanalysis.com › stocks › sabs

   • Cached

   Aug 9, 2024 · SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases.

9. finance.yahoo.com › news › sab-biotherapeuticsSAb Biotherapeutics Rebrands as SAB BIO - Yahoo Finance

   finance.yahoo.com › news › sab-biotherapeutics

   • Cached

   Jun 20, 2024 · MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing...

10. stockanalysis.com › stocks › sabsSAB Biotherapeutics, Inc. (SABS) - Stock Analysis

    stockanalysis.com › stocks › sabs

    • Cached

    2 days ago · SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes. SIOUX FALLS, S.D., Nov. 14, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ: SABS), a clinical stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-h...